Table 1.
Baseline Demographics and Clinical Characteristics
| Demographic or Clinical Characteristic | Placebo (n = 47) |
Linifanib 7.5 mg (n = 44) |
Linifanib 12.5 mg (n = 47) |
P* | |||
|---|---|---|---|---|---|---|---|
| No. of Patients | % | No. of Patients | % | No. of Patients | % | ||
| Age, years | |||||||
| Median | 61.0 | 61.5 | 60.0 | ||||
| Range | 44 to 79 | 35 to 79 | 43 to 79 | ||||
| < 65 | 30 | 63.8 | 31 | 70.5 | 34 | 72.3 | .681 |
| ≥ 65 | 17 | 36.2 | 13 | 29.5 | 13 | 27.7 | |
| Male | 27 | 57.4 | 25 | 56.8 | 27 | 57.4 | 1.000 |
| Race | .685 | ||||||
| White | 42 | 89.4 | 41 | 93.2 | 41 | 87.2 | |
| Black | 2 | 4.3 | 0 | 0 | 2 | 4.3 | |
| Asian | 2 | 4.3 | 3 | 6.8 | 2 | 4.3 | |
| Other | 1 | 2.1 | 0 | 0 | 2 | 4.3 | |
| Country | .835 | ||||||
| United States | 13 | 27.7 | 13 | 29.5 | 11 | 23.4 | |
| Outside of United States | 34 | 72.3 | 31 | 70.5 | 36 | 76.6 | |
| Smoker | 39 | 83.0 | 39 | 88.6 | 38 | 80.9 | .592 |
| ECOG PS | .633 | ||||||
| 0 | 15 | 31.9 | 13 | 29.5 | 16 | 34.0 | |
| 1 | 32 | 68.1 | 31 | 70.5 | 31 | 66.0 | |
| Histology | |||||||
| Adenocarcinoma | 42 | 89.4 | 40 | 95.2 | 40 | 85.1 | |
| Large cell | 0 | 0 | 2 | 5.3 | 3 | 6.4 | |
| Other† | 5 | 10.6 | 0 | 0 | 4 | 8.5 | |
| Disease | .907 | ||||||
| Locally advanced | 4 | 8.5 | 2 | 4.8 | 2 | 4.3 | |
| Metastatic | 43 | 91.5 | 40 | 95.2‡ | 45 | 95.7 | |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status.
*
P value for differences among treatment groups by Fisher's exact test.
†
Other tumor types were classified as non–small-cell carcinoma (n = 3), bronchoalveolar carcinoma (n = 2), planocellular nonsquamous lung cancer (n = 2), squamous cell carcinoma (n = 1), and nonsquamous carcinoma (n = 1).
‡
Two patients had missing data.